Borrelia valaisiana in Cerebrospinal Fluid by Diza, Eudoxia et al.
LETTERS
sive alternative to glycopeptides for
the treatment of MRSA infections.
Data from the United States and
Europe have shown that vancomycin-
intermediate  S. aureus isolates also
remain susceptible to some of the con-
ventional antimicrobial drugs, includ-
ing co-trimoxazole (5). If their effica-
cy in vivo is validated by clinical tri-
als, use of these conventional drugs
would not only reduce the load on
overstretched health care budgets but
reduce the use of vancomycin, there-
fore decreasing the risk of isolates
continuing to develop vancomycin
resistance.
Tariq Butt,* Rifat Nadeem Ahmad,*
Muhammad Usman,* 
and Abid Mahmood*
*Armed Forces Institute of Pathology,
Rawalpindi, Pakistan
References
1. Bishara J, Pitlik S, Samra Z, Levy I, Paul
M, Leibovici L. Co-trimoxazole–sensitive,
methicillin-resistant  Staphylococcus
aureus, Israel, 1988–1997. Emerg Infect
Dis. 2003;9:1168–9.
2. Hafiz S, Hafiz AN, Ali L, Chughtai AS,
Memon B, Ahmed A, et al. Methicillin
resistant  Staphylococcus aureus: a multi-
centre study. J Pak Med Assoc.
2002;52:312–4.
3.  National Committee for Clinical
Laboratory Standards. Performance stan-
dards for antimicrobial disk susceptibility
tests. 7th ed. Approved standard M2-A7.
Wayne (PA): The Committee; 2000. 
4.  World Health Organization Collaborating
Centre for Drug Statistics Methodology.
Guidelines for ATC classification and DDD
assignment. Oslo: The Centres; 1996. 
5.  Tenover FC, Biddle JW, Lancaster MV.
Increasing resistance to vancomycin and
other glycopeptides in Staphylococcus
aureus. Emerg Infect Dis. 2001;7:327–32.
Address for correspondence: Tariq Butt,
Department of Microbiology, Armed Forces
Institute of Pathology, Rawalpindi, Pakistan;
fax: 92-51-9271247; email: tariqbutt24@
yahoo.com
Borrelia valaisiana
in Cerebrospinal
Fluid 
To the Editor: Lyme borreliosis is
the most common tickborne human
disease in the Northern Hemisphere.
The incidence of the disease is not the
same throughout Europe; in southern
Europe, the incidence ranges from
43% in Croatia to 1.1% in Greece.
Suspected borreliosis cases have been
reported in Greece, none were con-
firmed.  Ixodes ricinus, the principal
tick vector of Borrelia burgdorferi in
Europe, is found in northern Greece.
A low prevalence of B. burgdorferi
antibodies was found in healthy per-
sons in Greece (1,2); a frequency of
7.3% was found in arthritis patients
(1), while a frequency of 16.9% was
found in patients with neurologic dis-
orders (E. Diza, unpub. data). 
Polymerase chain reaction (PCR)
has been used to detect B. burgdorferi
DNA in humans and to determine
genospecies (3). Isolates found in the
United States have constituted a
homogeneous group. In Europe, five
different genospecies from the origi-
nal  B. burgdorferi, now called
burgdorferi sensu lato complex, have
been described: B. burgdorferi sensu
stricto,  B. garinii,  B. afzelii, B.
valaisiana, and B. lusitaniae. Patho-
genicity for humans remains
uncertain for B. valaisiana and  B.
lusitaniae (4).
Neuroborreliosis, the most serious
manifestation of disseminated Lyme
disease, has become the most fre-
quently recognized arthropodborne
infection of the nervous system in the
United States and Europe. B. garinii,
B. afzelii, and B. burgdorferi sensu
stricto are confirmed causes of neu-
roborreliosis (5); however, B.
valaisiana has not been isolated from
cerebrspinal fluid (CSF) until this
report.
We report the genetic detection of
B. valaisiana in the CSF of a 61-year-
old man with a history of spastic para-
paresis, which is strong clinical evi-
dence of advanced neuroborreliosis.
Symptoms, mainly difficulty in walk-
ing, began approximately 10 years
earlier, with a slow progressive course
of neuroborreliosis. His medical his-
tory showed an unidentified sexually
transmitted disease in 1982, an unde-
fined episode of arthritis in the lower
limbs in 1990, and a nonspecific rash
in the genitals in 1995. The patient
lived in South Africa from 1961 to
1997 and visited Thassos Island in
northern Greece every year. The neu-
rologic examination demonstrated an
intense pyramidal spasticity in the
lower limbs and moderate weakness
(Medical Research Council grade 3)
of the proximal muscles. Serial mag-
netic resonance imaging (MRI) of the
brain showed small hyperintensities
in the periventricular area on T2-
weighted images; MRI of the spinal
cord showed no abnormalities.
Multiple sclerosis, B12 deficiency,
human T-cell lymphotrophic virus-1
infection, structural inflammatory
lesions of the spinal cord, motor neu-
ron disease, and hereditary spastic
paraplegia have been excluded. The
patient was treated occasionally with
intravenous penicillin G, as well as
with corticosteroids, but no clinical
improvement was achieved. Venereal
disease reaction level was negative
and all tests for syphilis in CSF were
negative. 
DNAwas extracted from CSF, and
a region of the chromosomal flagellin
gene of B. burgdorferi was amplified
by nested PCR (3). B. afzelii (VS461)
DNA was used as a positive control.
All precautions were taken to avoid
contamination. The amplified PCR
product was sequenced, and the
sequence (Th1) was deposited in
GenBank with the accession no.
AY270021. Phylogenetic analysis
showed that strain Th1 was clustering
with strains belonging to B.
valaisiana  genomic group.
Specifically, a nucleotide difference
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of 0.38% was observed among Th1
and isolates Ku10 and To76 (acces-
sion no. AYO83505 and AYO83504,
respectively), which belong to B.
valaisiana  genomic group and were
isolated from ricinus in Sweden (6). A
genetic difference of 0.77% was
observed between Th1 and B.
valaisiana strain Tr29 (accession no.
ABO91805) isolated from I. ricinus in
Turkey (7), while the genetic differ-
ence between Th1 and B. burgdorferi
(X15661) was much greater, 6.83%.
This report is the first of genetic
detection of B. valaisiana in CSF,
which indicates a probable associa-
tion of this genospecies with disease
in humans. B. valaisiana has been iso-
lated from I. ricinus ticks collected
from vegetation and from ticks
engorged on birds, in several
European countries, including Turkey
(7). The pathogenic capabilities of B.
valaisiana are still uncertain; it has
been detected by PCR and restriction
fragment length polymorphism analy-
sis in skin biopsy specimens from two
erythema migrans patients and from
patients with mixed infection (erythe-
ma migrans and acrodermatitis chron-
ica atrophicans) (4). Indirect evidence
suggests that B. valaisiana is involved
in some chronic clinical manifesta-
tions (8).
Borreliosis is difficult to diagnose
by serologic evaluation and Western
blot interpretation. In our patient, no
intrathecal antibodies were produced
to support clinical suspicion of dis-
ease. The low antibody titers could be
attributed to antigenic variation
between B. valaisiana and B. burgdor-
feri sensu stricto, which was used as
antigen because no commercial kit is
specific for B. valaisiana. Differences
between the strain causing infection
and the antigen may play a role in the
false-negative results (9). The low
antibody response in our patient could
be caused by antimicrobial drugs and
corticosteroid medication. 
The high homology of the
nucleotide sequence from our patient
and respective B. valaisiana se-
quences from other European coun-
tries suggests that he likely was infect-
ed in Greece. The status of Lyme dis-
ease in southern Africa is unknown,
but Ixodes spp. ticks have been found
there, and preliminary evidence indi-
cates that the disease may occur in
humans in South Africa (10).
We detected B. valaisiana DNA in
CSF of a patient with slow progres-
sive spastic paraparesis, which sug-
gests that this microorganism might
be the causative agent of the disease.
Nucleotide sequence information of
Borrelia strains from clinical cases
and ticks from different countries will
elucidate the molecular epidemiology
of the disease.
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Baylisascaris 
procyonis
in California 
To the Editor: We read with inter-
est the article of Roussere et al. on the
distribution of Baylisascaris procyo-
nis eggs in northern California com-
munities (1). The widespread dissem-
ination and high density of raccoon
latrines in residential areas clearly
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